Results 111 to 120 of about 18,836 (198)

Pharmacokinetic parameter values of posaconazole by age group and dosing cohort following single and multiple dose administration of posaconazole oral suspension.

open access: yes, 2019
Pharmacokinetic parameter values of posaconazole by age group and dosing cohort following single and multiple dose administration of posaconazole oral suspension.
Amanda Paschke (6508913)   +13 more
core   +1 more source

Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers.

open access: yes, 2010
Contains fulltext : 88741.pdf (Publisher’s version ) (Open Access)OBJECTIVES: To manage the interaction between fosamprenavir/ritonavir and posaconazole, we hypothesized that ritonavir can be replaced by posaconazole as an alternative ...
R. J. M. Bruggemann   +13 more
core   +1 more source

Plasma Concentrations of Prophylactic Posaconazole and Risk Factors for Subtherapeutic Exposure in Taiwanese Patients with Hematologic Malignancies

open access: yesDrug Design, Development and Therapy
Hsing-Yu Lin,1,* Shu-Chen Hu,2,* Tsung-Yu Pai,1 Fang-Ju Lin,1,3,4 Chien-Chih Wu1,3 1Department of Pharmacy, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan; 2Department of Pharmacy ...
Lin HY, Hu SC, Pai TY, Lin FJ, Wu CC
doaj  

The effectiveness and safety of posaconazole enteric-coated tablet versus oral suspension in invasive fungal infections

open access: yesScientific Reports
Posaconazole enteric-coated tablet and oral suspension are two oral drugs in the treatment of invasive fungal infections (IFIs). This study compared the effectiveness and safety between posaconazole enteric-coated tablet and oral suspension, and provided
Yi-Lei Yang   +4 more
doaj   +1 more source

Azole resistance among clinical <i>Aspergillus fumigatus</i> species complex isolates in Greece: first detection of TR<sub>46</sub>-mediated resistance and azole-resistant cryptic species. [PDF]

open access: yesJAC Antimicrob Resist
Siopi M   +11 more
europepmc   +1 more source

Evaluation of Posaconazole Use Within the IU Health System

open access: yes, 2015
Background: Posaconazole is a broad spectrum antifungal approved for prophylaxis of invasive fungal infections caused by Candida and Aspergillosis species in immunocompromised patients and for treatment of oropharyngeal candidiasis.
Harmon, Eric
core  

<i>In vitro</i> activity profiles and temporal trends in reduced susceptibility to azoles in <i>Coccidioides</i> in the United States. [PDF]

open access: yesAntimicrob Agents Chemother
Wiederhold NP   +6 more
europepmc   +1 more source

Exophiala jeanselmei Lower Extremity Phaeohyphomycosis in a Solid Organ Transplant Recipient. [PDF]

open access: yesAm J Trop Med Hyg
Hall AD   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy